Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrow, Matthew P, Kraynyak, Kimberly A, Sylvester, Albert J, Shen, Xuefei, Amante, Dinah, Sakata, Lindsay, Parker, Lamar, Yan, Jian, Boyer, Jean, Roh, Christian, Humeau, Laurent, Khan, Amir S, Broderick, Kate, Marcozzi-Pierce, Kathleen, Giffear, Mary, Lee, Jessica, Trimble, Cornelia L, Kim, J Joseph, Sardesai, Niranjan Y, Weiner, David B, Bagarazzi, Mark L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147865/
https://www.ncbi.nlm.nih.gov/pubmed/28054033
http://dx.doi.org/10.1038/mto.2016.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147865/
https://www.ncbi.nlm.nih.gov/pubmed/28054033
http://dx.doi.org/10.1038/mto.2016.25

Ejemplares similares